PRME News

With just two IPOs, it was the slowest October for the IPO market since 2011, though it was also the first month this year to produce only $100+ million IPOs, as small issuers continued to delay amid rising scrutiny. Intel's driver-assistance tech unit Mobileye (MBLY) and preclinical gene editing biotech Prime Medicine (PRME) were the only...read more

Prime Medicine, a preclinical biotech developing novel gene editing therapies for various diseases, raised $175 million by offering 10.3 million shares at $17, within the range of $16 to $18. The company offered 1.4 million more shares than anticipated. Prime Medicine is developing one-time curative genetic therapies using Prime Editing technology, and currently has a pipeline of...read more

A handful of deals are scheduled to price in the week ahead, led by large biotech Prime Medicine (PRME), which would be the first sizable IPO of the fourth quarter. Along with the deals already scheduled, Intel’s Mobileye (MBLY) will be eligible to launch its IPO and could join the calendar in the week ahead. The self-driving tech...read more

Three SPACs began trading this past week, joined by one micro-cap, though it was too small to be included in our IPO stats. Two small IPOs submitting initial filings. The biggest news came from the pipeline, as gene editing biotech Prime Medicine (PRME) launched its $151 million IPO. It is expected to list on the Nasdaq in the week ahead. The week’s blank...read more